Literature DB >> 11701741

Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: importance of the ligand-binding domain for intracellular GR trafficking.

T Kino1, R H Stauber, J H Resau, G N Pavlakis, G P Chrousos.   

Abstract

The syndrome of familial or sporadic glucocorticoid resistance is characterized by hypercortisolism without the clinical stigmata of Cushing syndrome. This condition is usually caused by mutations of the human GR, a ligand-activated transcription factor that shuttles between the cytoplasm and the nucleus. A pathological human mutant receptor, in which Ile was replaced by Asn at position 559, had negligible ligand binding, was transcriptionally extremely weak, and exerted a transdominant negative effect on the transactivational activity of the wild-type GR, causing severe glucocorticoid resistance in the heterozygous state. To understand the mechanism of this mutant's trans-dominance, we constructed several N-terminal GR fusion chimeras to green fluorescent protein (GFP) and demonstrated that their transactivational activities were similar to those of the original proteins. The GFP-human (h) GRalphaI559N chimera was predominantly localized in the cytoplasm, and only high doses or prolonged glucocorticoid treatment triggered complete nuclear import that took 180 vs. 12 min for GFP-hGRalpha. Furthermore, hGRalphaI559N inhibited nuclear import of the wild-type GFP-hGRalpha, suggesting that its trans-dominant activity on the wild-type receptor is probably exerted at the process of nuclear translocation. As the ligand-binding domain (LBD) of the GR appears to play an important role in its nucleocytoplasmic shuttling, we also examined two additional GR-related fusion proteins. The natural hGR isoform beta (GFP-hGRbeta), containing a unique LBD, was transactivation-inactive, moderately trans-dominant, and localized instantaneously and predominantly in the nucleus; glucocorticoid addition did not change its localization. Similarly, GFP-hGR514, lacking the entire LBD, was instantaneously and predominantly localized in the nucleus regardless of presence of glucocorticoids. Using a cell fusion system we demonstrated that nuclear export of GFP-hGRalphaI559N (250 min) and GFP-hGRbeta (300 min) was drastically impaired compared with that of GFP-hGRalpha (50 min) and GFP-hGR514 (50 min), suggesting that an altered LBD may impede the exit of the GR from the nucleus. We conclude that the trans-dominant negative effect of the pathological mutant is exerted primarily at the translocation step, whereas that of the natural isoform beta is exerted at the level of transcription.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701741     DOI: 10.1210/jcem.86.11.8017

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

Review 1.  Chrousos syndrome: a seminal report, a phylogenetic enigma and the clinical implications of glucocorticoid signalling changes.

Authors:  Evangelia Charmandari; Tomoshige Kino
Journal:  Eur J Clin Invest       Date:  2010-08-19       Impact factor: 4.686

Review 2.  Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder.

Authors:  Evangelia Charmandari; Tomoshige Kino; Takamasa Ichijo; George P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  2008-03-04       Impact factor: 5.958

3.  CRTC2 Is a Coactivator of GR and Couples GR and CREB in the Regulation of Hepatic Gluconeogenesis.

Authors:  Micah J Hill; Shigeru Suzuki; James H Segars; Tomoshige Kino
Journal:  Mol Endocrinol       Date:  2015-12-10

4.  Glucocorticoid receptor mutants demonstrate increased motility inside the nucleus of living cells: time of fluorescence recovery after photobleaching (FRAP) is an integrated measure of receptor function.

Authors:  Tomoshige Kino; Szu-Heng Liou; Evangelia Charmandari; George P Chrousos
Journal:  Mol Med       Date:  2004 Jul-Dec       Impact factor: 6.354

5.  A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: dissociation of the transactivating and transreppressive activities.

Authors:  Nicolas C Nicolaides; Michael L Roberts; Tomoshige Kino; Geoffrey Braatvedt; Darrell E Hurt; Eleni Katsantoni; Amalia Sertedaki; George P Chrousos; Evangelia Charmandari
Journal:  J Clin Endocrinol Metab       Date:  2014-01-31       Impact factor: 5.958

Review 6.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

7.  Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma.

Authors:  Michael A Tessel; Ashley L Benham; Nancy L Krett; Steven T Rosen; Preethi H Gunaratne
Journal:  Horm Cancer       Date:  2011-06       Impact factor: 3.869

8.  Identification of natural human glucocorticoid receptor (hGR) mutations or polymorphisms and their functional consequences at the hormone-receptor interaction level.

Authors:  Evangelia Charmandari; George P Chrousos; Tomoshige Kino
Journal:  Methods Mol Biol       Date:  2009

9.  Structural Analysis on the Pathologic Mutant Glucocorticoid Receptor Ligand-Binding Domains.

Authors:  Darrell E Hurt; Shigeru Suzuki; Takafumi Mayama; Evangelia Charmandari; Tomoshige Kino
Journal:  Mol Endocrinol       Date:  2016-01-08

Review 10.  The human glucocorticoid receptor: molecular basis of biologic function.

Authors:  Nicolas C Nicolaides; Zoi Galata; Tomoshige Kino; George P Chrousos; Evangelia Charmandari
Journal:  Steroids       Date:  2009-10-07       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.